PI4KA and hepatocellular carcinoma: We recently established a drug regimen based on pharmacological inhibition of PI4KA and CKIα (designated PCi) enhancing RNA replication of gt1b WT isolates by approximately 100-fold, allowing infection of Huh7 hepatoma cells with several patient-derived gt1b sera [18].